Pangea Natural Foods files amended financials, MD&A

Mr. Pratap Sandhu reports PANGEA ANNOUNCES FILING OF AMENDED AND RESTATED INTERIM FINANCIAL STATEMENTS AND MANAGEMENT'S DISCUSSION AND ANALYSIS Pangea Natural Foods Inc., as a result of a continuous disclosure review by the British Columbia Securities Commission, has filed amended and restated interim financial statements and management's discussion and analysis (MD&A) for the six-month period ended April 30, 2025, and the nine-month period ended July 31, 2025, to provide additional disclosure Amended and restated interim financial statements and MD&A (management's discussion and analysis) The company has amended and restated its interim MD&A and interim financial statements for the six-month period ended April 30, 2025, and the nine-month period ended July 31, 2025, to include the following additional disclosure, among other things: The company's accounting policy choice relating to its acquisition of Amino Innovations Inc. on April 9, 2025; The company's impairment indicator assessment of the company's intangible asset and goodwill as of July 31, 2025. The amended and restated MD&A and interim financial statements have been filed under the company's issuer profile on SEDAR+. About Pangea Natural Foods Inc. Pangea Natural Foods is a North American manufacturer specializing in clean-label foods and innovative wellness products. Through its subsidiary, Amino Innovations, the company offers advanced, needle-free peptide therapies that support recovery, cognitive function and overall health. We seek Safe Harbor.